A systematic review and economic model of the effectiveness and ...

tutoring on the behavior and achievement of lower
class hyperactive children. J Learn Disabil
1971;4:509–17.
48. Dopfner M, Bonaschewski T, Schmidt J, Uebel H,
Schmeck K, Gerber WD, et al. Long-acting
methylphenidate preparation in children with
ADHD – a multicenter study. Nervenheilkd
2003;22:85–92.
49. DuPaul GJ, Rapport MD. Does methylphenidate
normalize the classroom performance of children
with attention deficit disorder? J Am Acad Child
Adolesc Psychiatry 1993;32:190–9.
50. Efron D, Jarman F, Barker M. Methylphenidate
versus dexamphetamine in children with attention
deficit disorder: a double-blind, crossover trial.
Pediatrics 1997;100:e6.
51. Elia J, Borcherding BG, Rapoport JL, Keysor CS.
Methylphenidate and dextroamphetamine
treatments of hyperactivity: are there true
nonresponders? Psychiatry Res 1991;36:141–55.
52. Fine S, Johnston C. Drug and placebo side effects
in methylphenidate–placebo trial for attention
deficit hyperactivity disorder. Child Psychiatry Hum
Dev 1993;4:25–30.
53. Firestone P, Crowe D, Goodman JT, McGrath P.
Vicissitudes of follow-up studies: differential effects
of parent training and stimulant medication with
hyperactives. Am J Orthopsychiatry 1986;56:184–94.
54. Fischer M, Newby RF. Assessment of stimulant
response in ADHD children using a refined
multimethod clinical protocol. J Clin Child Psychol
1991;20:232–44.
55. Fitzpatrick PA, Klorman R, Brumaghim JT,
Borgstedt AD. Effects of sustained-release and
standard preparations of methylphenidate on
attention deficit disorder. J Am Acad Child Adolesc
Psychiatry 1992;31:226–34.
56. Gillberg C, Melander H, von Knorring AL,
Janols LO, Thernlund G, Hagglof B, et al. Longterm
stimulant treatment of children with
attention-deficit hyperactivity disorder symptoms.
A randomized, double-blind, placebo-controlled
trial. Arch Gen Psychiatry 1997;54:857–64.
57. Gittelman-Klein R, Klein DF, Katz S, Saraf K,
Pollack E. Comparative effects of methylphenidate
and thoridazine in hyperkinetic children. I.
Clinical results. Arch Gen Psychiatry
1976;33:1217–31.
58. Greenberg LM, Deem MA, McMahon S. Effects of
dextroamphetamine, chlorpromazine, and
hydroxyzine on behavior and performance in
hyperactive children. Am J Psychiatry
1972;129:532–9.
59. Greenhill LL, Findling RL, Swanson JM, Group
AS. A double-blind, placebo-controlled study of
modified-release methylphenidate in children with
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
attention-deficit/hyperactivity disorder. Pediatrics
2002;109:E39.
60. Handen B, Feldman HM, Lurier A, Murray PJ.
Efficacy of methylphenidate among preschool
children with developmental disabilities and
ADHD. J Am Acad Child Adolesc Psychiatry
1999;38:805–12.
61. Hoeppner JA, Hale JB, Bradley AM, Byrnes M,
Coury DL, Lennie L, et al. A clinical protocol for
determining methylphenidate dosage levels in
ADHD. J Attention Disord 1997;2:19–30.
62. James RS, Sharp WS, Bastain TM, Lee PP,
Walter JM, Czarnolewski M, et al. Double-blind,
placebo-controlled study of single-dose
amphetamine formulations in ADHD. J Am Acad
Child Adolesc Psychiatry 2001;40:1268–76.
63. Kelsey D, Sumner C, Casat CD, Coury DL,
Quintana H, Saylor KE, et al. Once-daily
atomoxetine treatment for children with attentiondeficit/hyperactivity
disorder, including an
assessment of evening and morning behaviour: a
double-blind, placebo controlled trial. Pediatrics
2004;114:e1–8.
64. Kemner JE, Starr HL, Ciccone PE,
Hooper-Wood CG, Crockett S. Treatment outcomes of
OROS(R) methylphenidate compared with atomoxetine
in children with ADHD: a multicenter, randomized,
prospective study. Washington, DC: McNeil
Consumer and Specialty Pharmaceuticals; 2004.
65. Klein RG, Abikoff H. Behavior therapy and
methylphenidate in the treatment of children with
ADHD. J Atten Disord 1997;2:89–114.
66. Klorman R, Coons HW, Borgstedt AD. Effects of
methylphenidate on adolescents with a childhood
history of attention deficit disorder: I. Clinical
findings [published erratum appears in J Am Acad
Child Adolesc Psychiatry 1987;26:820 (Ref. 304)].
J Am Acad Child Adolesc Psychiatry 1987;26:363–7.
67. Klorman R, Brumaghim JT, Fitzpatrick PA,
Borgstedt AD. Clinical effects of a controlled trial
of methylphenidate on adolescents with attention
deficit disorder. J Am Acad Child Adolesc Psychiatry
1990;29:702–9.
68. Klorman R, Brumaghim JT, Fitzpatrick PA,
Borgstedt AD, Strauss J. Clinical and cognitive
effects of methylphenidate on children with
attention deficit disorder as a function of
aggression/oppositionality and age. J Abnorm
Psychol 1994;103:206–21.
69. Kolko DJ, Bukstein OG, Barron J.
Methylphenidate and behavior modification in
children with ADHD and comorbid ODD or CD:
main and incremental effects across settings. J Am
Acad Child Adolesc Psychiatry 1999;38:578–86.
70. Kratochvil CJ, Heiligenstein JH, Dittmann R,
Spencer TJ, Biederman J, Wernicke J, et al.
Atomoxetine and methylphenidate treatment in
135